New hope for lupus patients: sirolimus shows promise in phase 3 trial

NCT ID NCT04582136

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times

Summary

This study tests whether adding sirolimus to standard lupus therapy helps control active disease better than a placebo. It involves 146 adults with lupus who still have symptoms despite usual care. The main goal is to see if more people achieve a meaningful reduction in disease activity after 24 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100053, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

Conditions

Explore the condition pages connected to this study.